Keyword: WuXi AppTec

Markets & Companies

Delivering Quality with Speed for European Market

20.03.2023 -

In this interview, Jinling Chen, head of WuXi STA’s drug product business, and Jamie Andrews, site head of WuXi STA’s Couvet facility, explain the company’s strategy and...


WuXi STA Opens new Parenteral Formulation Line

02.12.2022 -

WuXi STA has started up a new parenteral formulation line at its drug product site in Wuxi City, China. The company’s second line for parenteral drug product clinical and...


WuXi Opens Lipid Nanoparticle Facility

13.09.2022 -

WuXi STA has opened a sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its campus in Wuxi city, China, in response to rising demand...


WuXi Expands API Competence in Asia

22.07.2022 -

WuXi AppTec and its subsidiary Wuxi STA have announced several investments in manufacturing and research in Asia, with the Changzou campus in China’s Jiangsu Province a...


Wuxi ATU Collaborates with Singapore’s BTI

02.05.2022 -

WuXi Advanced Therapies (Wuxi ATU), US-based CDMO offshoot of WuXi AppTec, is joining up with Singapore’s Bioprocessing Technology Institute (BTI) to advance cell and...


WuXi AppTec Buys British CDMO Oxgene

11.03.2021 -

China’s WuXi AppTec has acquired British gene therapy CDMO Oxgene, making the Oxford-based company a wholly owned subsidiary of the contract testing, development and...


WuXi AppTec Boosts Biometrics with Pharmapace

13.05.2019 - China’s WuXi AppTec has acquired US clinical research services company Pharmapace, boosting its biometrics capabilities in Europe and the US. Financial details were not disclosed...

Strategy & Management

Significant Value Creation

03.09.2015 - In September 2014, Merck announced the €13.1 billion acquisition of Sigma-Aldrich, which by mid-August has received antitrust clearance from all relevant jurisdictions including...